

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/146662 A1

(51) International Patent Classification:

A61P 37/00 (2006.01) C07K 16/46 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/IB2025/050090

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,230 05 January 2024 (05.01.2024) US
63/716,619 05 November 2024 (05.11.2024) US

(71) Applicant: **IMMUNOCORE LIMITED** [GB/GB]; 92
PARK DRIVE, MILTON PARK, ABINGDON, OXON
OX14 4RY (GB).

(72) Inventors: **CURNOCK, Adam**; c/o Immunocore Limited,
92 Park Drive, Milton Park, Abingdon, Oxon OX14 4RY
(GB). **OVERTON, David**; c/o Immunocore Limited, 92
Park Drive, Milton Park, Abingdon, Oxon OX14 4RY (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CD1A-PD-1 BISPECIFIC AGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS

(57) Abstract: The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).



WO 2025/146662 A1